Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Unknown 2Recruiting 2

Sponsor Class

OTHER_GOV 4OTHER 2INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 1

Conditions

Colorectal Neoplasms 2Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1

Interventions

Cisplatin 50Capecitabine 42apatinib 34Radiotherapy 33Oxaliplatin 33Gemcitabine 33Cyclophosphamide 32Drug Therapy 31Paclitaxel 30Carboplatin 29tislelizumab 27Irinotecan 27Fluorouracil 26Docetaxel 26Bevacizumab 23Surgical Procedures, Operative 21Nivolumab 19pembrolizumab 18fludarabine 18Metformin 16Exercise 16camrelizumab 15Radiation 15S 1 (combination) 14Control Groups 14Blood Specimen Collection 14Pemetrexed 13Standard of Care 12anlotinib 11Neoadjuvant Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER_GOV × Etodolac × Clear all
NCT06839144 2025-07-11

OC-POP-PT

Tel-Aviv Sourasky Medical Center

Phase 2 Recruiting
60 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

NCT03838029 2019-11-20

BC-PC

Assaf-Harofeh Medical Center

Phase 2 Unknown
210 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT03919461 2019-04-18

COMPIT-2

Assaf-Harofeh Medical Center

Phase 2 Recruiting
200 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT00888797 2011-07-12

β-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence

Sheba Medical Center

Phase 3 Unknown
400 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡